Molecular Templates, Inc.
Customers
2
1 disclosed
Suppliers
0
None disclosed
Largest customer
33%
BMY · 3M to 2024-06-30
Named-customer revenue
—
No estimate available
Latest period
Jun 30, 2024
10-Q filed 2024-08-14
Customers 2
Companies Molecular Templates, Inc. discloses as major customers, as a share of Molecular Templates, Inc. revenue. 1 active, 1 lapsed.
| Company | % of Molecular Templates, Inc. revenue | Est. revenue | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| BMY BRISTOL MYERS SQUIBB CO |
33% | — | 3M 2024-06-30 | −66.0pp | Active | 10-Q 2024-08-14 |
Bristol-Myers Squibb accounted for approximately 33% and 97% of total revenues for the three months ended June 30, 2024 and 2023, respectively, and approximately 95% and 93% of total revenues for the six months ended June 30, 2024 and 2023, respectively.Biologic candidates developed by the Company require approvals or clearances from the U.S. Food and Drug Administration (the “FDA”) or international regulatory agencies prior to commercial sales. Bristol-Myers Squibb accounted for approximately 99% and 92% of total revenues for the three months ended March 31, 2024 and 2023, respectively.Biologic candidates developed by the Company require approvals or clearances from the U.S. Food and Drug Administration (the “FDA”) or international regulatory agencies prior to commercial sales. Bristol-Myers Squibb accounted for approximately 92% and 87% of total revenues for the years ended December 31, 2023 and 2022, respectively.Biologic candidates developed by the Company require approvals or clearances from the U.S. Food and Drug Administration or international regulatory agencies prior to commercial sales. Bristol-Myers Squibb accounted for approximately 84% and 100% of total revenues for the three months ended September 30, 2023 and 2022, respectively, and approximately 91% and 85% of total revenues for the nine months ended September 30, 2023 and 2022, respectively.Drug or biologic candidates developed by the Company require approvals or clearances from the U.S. Food and Drug Administration or international regulatory agencies prior to commercial sales. Bristol Myers Squibb accounted for approximately 97% and 100% of total revenues for the three months ended June 30, 2023 and 2022, respectively, and approximately 93% and 80% of total revenues for the six months ended June 30, 2023 and 2022, respectively. Bristol Myers Squibb accounted for approximately 92% and 70% of total revenues for the three months ended March 31, 2023 and 2022, respectively. Bristol Myers Squibb accounted for approximately 87% and 18% of total revenues for the years ended December 31, 2022 and December 31, 2021, respectively. Bristol Myers Squibb accounted for approximately 100% and 35% of total revenues for the three months ended September 30, 2022 and 2021, respectively and approximately 85% and 18% of total revenues for the nine months ended September 30, 2022 and 2021. Bristol Myers Squibb accounted for approximately 100% and 13% of total revenues for the three months ended June 30, 2022 and 2021, respectively and approximately 80% and 16% of total revenues for the six months ended June 30, 2022 and 2021. | ||||||
| TAK TAKEDA PHARMACEUTICAL CO LTD |
13% | — | FY 2022-12-31 | −21.0pp | Lapsed Last seen 2022-12-31 |
10-K 2023-03-30 |
Research and development revenue from a previously related party was with Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (“Takeda”) and were as follows (in thousands): Research and development revenue from a previously related party was with Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (“Takeda”) and were as follows (in thousands): Research and development revenue from a previously related party was with Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (“Takeda”) and were as follows (in thousands): Research and development revenue from a previously related party was revenue from research and development agreements with Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (“Takeda”) and were as follows (in thousands): Research and development revenue from related party relates to revenue from research and development agreements with Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (“Takeda”) and were as follows (in thousands): Research and development revenue from related party relates to revenue from research and development agreements with Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (“Takeda”) and were as follows (in thousands): Research and development revenue from related party relates to revenue from research and development agreements with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Ltd. (“Takeda”) and were as follows (in thousands): | ||||||
Alerts are coming
Get an email when Molecular Templates, Inc.'s disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.